192 related articles for article (PubMed ID: 21993845)
1. Anti-angiogenic agents in ovarian cancer: dawn of a new era?
Liu J; Matulonis UA
Curr Oncol Rep; 2011 Dec; 13(6):450-8. PubMed ID: 21993845
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis: a promising therapeutic target for ovarian cancer.
Bamias A; Pignata S; Pujade-Lauraine E
Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
[TBL] [Abstract][Full Text] [Related]
4. Role of chemotherapy in epithelial ovarian cancer.
Markman M
Minerva Ginecol; 2011 Jun; 63(3):287-97. PubMed ID: 21654613
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in the development of anti-angiogenic therapies for ovarian cancer.
Raja FA; Hook JM; Ledermann JA
Cancer Treat Rev; 2012 Oct; 38(6):662-72. PubMed ID: 22209539
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
Burger RA
Ann Oncol; 2011 Dec; 22 Suppl 8():viii65-viii68. PubMed ID: 22180405
[TBL] [Abstract][Full Text] [Related]
8. Emerging drugs for ovarian cancer.
Sugiyama T; Konishi I
Expert Opin Emerg Drugs; 2008 Sep; 13(3):523-36. PubMed ID: 18764727
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES; Wakabayashi M; Leong L
Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
11. Trebananib: an alternative anti-angiogenic strategy.
Gourley C
Lancet Oncol; 2014 Jul; 15(8):776-7. PubMed ID: 24950984
[No Abstract] [Full Text] [Related]
12. Targeted anti-vascular therapies for ovarian cancer: current evidence.
Hall M; Gourley C; McNeish I; Ledermann J; Gore M; Jayson G; Perren T; Rustin G; Kaye S
Br J Cancer; 2013 Feb; 108(2):250-8. PubMed ID: 23385789
[TBL] [Abstract][Full Text] [Related]
13. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
Hou MM; Wang Z; Janku F; Piha-Paul S; Naing A; Hong D; Westin S; Coleman RL; Sood AK; Tsimberidou AM; Subbiah V; Wheler J; Zinner R; Lu K; Meric-Bernstam F; Fu S
Oncotarget; 2016 Jun; 7(23):35132-43. PubMed ID: 27147567
[TBL] [Abstract][Full Text] [Related]
14. [Maintenance therapy in patients with advanced epithelial ovarian cancer-impact of anti-angiogenic molecular targeted agents in progress].
Takeuchi S; Sugiyama T
Gan To Kagaku Ryoho; 2014 Aug; 41(8):937-43. PubMed ID: 25132025
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of anti-angiogenic therapy in ovarian cancer (review).
Conteduca V; Kopf B; Burgio SL; Bianchi E; Amadori D; De Giorgi U
Int J Oncol; 2014 May; 44(5):1417-24. PubMed ID: 24626312
[TBL] [Abstract][Full Text] [Related]
16. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies for treatment of recurrent ovarian cancer.
Grisham RN; Hyman DM; Iyer G
Clin Adv Hematol Oncol; 2014 Mar; 12(3):158-62. PubMed ID: 24927263
[TBL] [Abstract][Full Text] [Related]
18. Advances in ovarian cancer therapy.
Cortez AJ; Tudrej P; Kujawa KA; Lisowska KM
Cancer Chemother Pharmacol; 2018 Jan; 81(1):17-38. PubMed ID: 29249039
[TBL] [Abstract][Full Text] [Related]
19. The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.
Markman M
Ann Oncol; 2011 Dec; 22 Suppl 8():viii69-viii71. PubMed ID: 22180406
[TBL] [Abstract][Full Text] [Related]
20. Clinical application of oxaliplatin in epithelial ovarian cancer.
Fu S; Kavanagh JJ; Hu W; Bast RC
Int J Gynecol Cancer; 2006; 16(5):1717-32. PubMed ID: 17009963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]